Home
Clinical Resources Search
PQI: Brentuximab Vedotin (Adcetris®) Neuropathy and Neutropenia Management

Brentuximab Vedotin (Adcetris®) Neuropathy and Neutropenia Management

Last Updated: November 12, 2025

By: Kirollos Hanna, PharmD, BCPS, BCOP | Kayla Randle, PharmD, BCOP

About this PQI

The purpose of this document is to discuss the clinical considerations and general management of toxicities related to brentuximab vedotin and its use across various indications.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI